Clinical Care of Ataxia Patients
The goal of this study is to better understand the clinical practices of providers caring for patients with hereditary ataxias. This includes geographic estimates of patient prevalence and prescription habits.
Link to Enroll: https://umich.qualtrics.com/jfe/form/SV_3qsNTK5Kj3wf9KS
About the Study
Eligible Ataxia Types
SCAs 1,2,3,6,7,8,10,12,27B, FRDA, RFC1/CANVAS, FXTAS, AT, EA1/2
Type of Study
Survey
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
07/28/2024
Estimated Completion Date
12/31/2026
IRB Approval #
HUM00255285
Location(s)
University of Michigan
109 Zina Pitcher Place, BSRB 4007
Ann Arbor, MI
Contact Information
Sharan Srinivasan
sharans@med.umich.edu
734-615-8116
What does participation in the study entail?
Completion of a one-time survey. This survey is anonymous, asking only country of practice. No other identifying information is requested.
What are the potential benefits for participants?
The results of this study will inform the greater ataxia community about the international prevalence of various hereditary ataxias by country of clinical care. Further, analysis of prescribing habits will allow clinicians to learn from each other and potentially improve patient outcomes.
What are the potential risks for participants?
There is no active intervention being performed and therefore no risk to participants.
Is there financial compensation?
No.
Is there travel reimbursement?
No.
Who is eligible?
Any clinician caring for patients with ataxia is eligible to take this survey.
Additional Information or Resources
Link to Enroll: https://umich.qualtrics.com/jfe/form/SV_3qsNTK5Kj3wf9KS
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
